1 / 47

Module 3

Module 3. Christa Clasen Ankara, 6./7. April 2006. Module 3. 3.1 Table of Content 3.2 Body of Data 3.2.S Drug Substance 3.2.P Drug Product 3.2.A Appendices 3.2.R Regional Information 3.3 Literature References. 3.2.S Drug Substance. 3.2.S.1 General Information

ronnie
Download Presentation

Module 3

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Module 3 Christa Clasen Ankara, 6./7. April 2006

  2. Module 3 • 3.1 Table of Content • 3.2 Body of Data • 3.2.S Drug Substance • 3.2.P Drug Product • 3.2.A Appendices • 3.2.R Regional Information • 3.3 Literature References Christa Clasen Ankara, 6./7. April 2006

  3. 3.2.S Drug Substance • 3.2.S.1 General Information • 3.2.S.2 Manufacture • 3.2.S.3 Characterisation • 3.2.S.4 Control of drug substance • 3.2.S.5 Reference Standards or Materials • 3.2.S.6 Container Closure System • 3.2.S.7 Stability Christa Clasen Ankara, 6./7. April 2006

  4. 3.2.S.1 General Information • 3.2.S.1.1 Nomenclature INN, Compendial name, chemical name, other name, laboratory codes, CAS – number • 3.2.S.1.2 Structure Physical form, structural formula (incl. stereochemistry) • 3.2.S.1.3 General Properties Physico-chemical characterisation (solubility, physical characteristics, polymorphism, other) Christa Clasen Ankara, 6./7. April 2006

  5. 3.2.S.2 Manufacture • 3.2.S.2.1 Manufacturer • 3.2.S.2.2 Description of Manufacturing Process and Process Controls • 3.2.S.2.3 Controls of Materials • 3.2.S.2.4 Control of Critical Steps and Intermediates • 3.2.S.2.5 Process Validation and/or Evaluation • 3.2.S.2.6 Manufacturing Process Development Christa Clasen Ankara, 6./7. April 2006

  6. 3.2.S.2 Manufacture • 3.2.S.2.1 Manufacturer • Address office • Address plant Company profile is not obligatory • If starting materials/ or used intermediates already contains a key-structure of the final drug substance, information of those manufacturer(s) are required Christa Clasen Ankara, 6./7. April 2006

  7. 3.2.S.2 Manufacture • 3.2.S.2.2 Description of Manufacturing Process and Process Controls Applicant‘s Part: • Synthetic route: overview • Flow chart • Brief narrative description of the process Christa Clasen Ankara, 6./7. April 2006

  8. 3.2.S.2 Manufacture 3.2.S.2.2 Description of Manufacturing Process and Process Controls Restricted Part: • Synthetic route: Overview • Flow chart including molecular formula, weights, yields, chemical structures of starting materials, intermediates, reagents and drug substance reflecting stereochemistry, operating conditions and used solvents • Narrative description of the process covering in more detail the information given in the flow-chart Christa Clasen Ankara, 6./7. April 2006

  9. 3.2.S.2 Manufacture • 3.2.S.2.3 Control of Materials • List of used raw materials identifying where each material is used in the process. • Control of starting materials (Specifications, Description of Test methods) • Control of solvents and other reagents (Specifications, Description of Test methods) • If starting materials already contains the key-structure of the final API, a synthesis-outline (including solvents, reagents, catalysts, potential Impurities) for these starting materials are required Christa Clasen Ankara, 6./7. April 2006

  10. 3.2.S.2. Manufacture • 3.2.S.2.4 Control of Critical Steps and Intermediates • Control of Intermediates (Specifications, Description of test methods) • Tests and acceptance criteria (with justification including experimental data) performed at critical steps identified in 3.2.S.2.2 Christa Clasen Ankara, 6./7. April 2006

  11. 3.2.S.2 Manufacture • 3.2.S.2.5 Process Validation and/or Evaluation Process Validation studies should be included (only for aseptic processes or sterilisation) In any case: Validation studies have to be perfomed and needs to be available at request Christa Clasen Ankara, 6./7. April 2006

  12. 3.2.S.2 Manufacture • 3.2.S.2.6 Manufacturing Process Development A description and discussion about the significant changes/improvements to the manufacturing process and/or manufacturing site of the drug substance is awaited Christa Clasen Ankara, 6./7. April 2006

  13. 3.2.S.3 Characterisation • 3.2.S.3.1. Eludication of Structure and other Characteristics • Evidence of the chemical structure (elemental analysis, mass spectrum, 1H-NMR, 13C-NMR, IR, UV, other) • Potential isomerism • Stereochemistry • Polymorphism Christa Clasen Ankara, 6./7. April 2006

  14. 3.2.S.3 Characterisation • 3.2.S.3.2. Impurities • List of potential impurities originating from the route of synthesis • List of potential impurities arising during the production and purification • List of actual existing impurities (synthesis by-products, degradation products) • List of potential residual solvents • List of actual residual solvents in API • Evidence of the chemical structure (elemental analysis, mass spectrum, 1H-NMR, 13C-NMR, IR, UV, other) for each Impurity Christa Clasen Ankara, 6./7. April 2006

  15. 3.2.S.4 Control of Drug Substance • 3.2.S.4.1 Specification • According to which pharmacopoeia, in-house • Characteristics • Identification tests • Purity tests (including limits for known, total, unidentified single and unidentified total) • Other tests • Assay Christa Clasen Ankara, 6./7. April 2006

  16. 3.2.S.4 Control of Drug Substance • 3.2.S.4.2 Analytical Procedures Reference to pharmacopoeia, or detailed description of all tests • 3.2.S.4.3 Validation of Analytical Procedures Validation of all used methods according to ICH Guidelines Q2A and Q2B (if they are not pharmacopoeial) Christa Clasen Ankara, 6./7. April 2006

  17. 3.2.S.4 Control of Drug Substance • 3.2.S.4.4 Batch analysis • Batches tested (date of manufacture, place of manufacture, batch size) • Results of tests (3 - 5 consecutive certificates of analysis) • 3.2.S.4.5 Justification of the drug substance specification • Comments on the Choice of Routine Tests • Justification of Specification Limits Christa Clasen Ankara, 6./7. April 2006

  18. 3.2.S.5. Reference Standards or Materials • List of used Reference Standards or Materials • Preparation of Reference Standards, if appropriate • Elucidation of Structure for synthesized Materials • Specification for Reference materials • Description of Test Methods • Validation of Analytical Methods if not covered by 3.2.S.4.3 Christa Clasen Ankara, 6./7. April 2006

  19. 3.2.S.6 Container Closure System • Description of Container Closure System including Identity of Materials and their specification • Discussion of suitability of Packaging material Christa Clasen Ankara, 6./7. April 2006

  20. 3.2.S.7 Stability • 3.2.S.7.1. Stability Summaries and Conclusions • Program of stability studies (including forced degradation studies if appropriate, e.g. testing parameters, packaging material, storage conditions, batch number, manufacturing date, batch size • Conclusion Christa Clasen Ankara, 6./7. April 2006

  21. 3.2.S.7 Stability • 3.2.S.7.2 Post-approval Stability Protocol and Stability Commitment Program of stability study including testing parameters, packaging material, storage conditions, batch number, manufacturing date, batch size, which will be performed post-approval Christa Clasen Ankara, 6./7. April 2006

  22. 3.2.S.7 Stability • 3.2.S.7.3 Stability data Results of: • Long-term study (initial, 3, 6, 9, 12, 18, 24, 36 months) for at least 3 batches • Accelerated study (initial, 1, 2, 3, 6 months) for the same batches as long-term study • Intermediate study (initial, 3, 6, 9, 12, 18, 24, 36 months) for at least 3 batches, if appropriate • Forced degradation study (alkaline conditions, acidic conditions, higher temperature, oxidative condition, light) Christa Clasen Ankara, 6./7. April 2006

  23. 3.2.P Drug Product • 3.2.P.1 Description and Compostion of the Drug Product • 3.2.P.2 Pharmaceutical Development • 3.2.P.3 Manufacture • 3.2.P.4 Control of Excipients • 3.2.P.5 Control of Drug Product • 3.2.P.6 Reference Standards or Materials • 3.2.P.7 Container Closure System • 3.2.P.8 Stability Christa Clasen Ankara, 6./7. April 2006

  24. 3.2.P.1 Description and Composition of the Drug Product • Description of dosage form • List of components and their amount • Function of components • Reconstitution diluent(s) Christa Clasen Ankara, 6./7. April 2006

  25. 3.2.P.2 Pharmaceutical Development • 3.2.P.2.1 Components of Drug Product • 3.2.P.2.2 Drug Product • 3.2.P.2.3 Manufacturing Process Development • 3.2.P.2.4 Container Closure System • 3.2.P.2.5 Microbiological Attributes • 3.2.P.2.6 Compatibility Christa Clasen Ankara, 6./7. April 2006

  26. 3.2.P.2 Pharmaceutical Development • 3.2.P.2.1 Components of the Drug Product • 3.2.P.2.1.1 Drug Substance • Compatibility with Excipients • Key physicochemical Characteristics • 3.2.P.2.1.2 Excipients • Justification of Choice Christa Clasen Ankara, 6./7. April 2006

  27. 3.2.P.2 Pharmaceutical Development • 3.2.P.2.2 Drug Product • 3.2.P.2.2.1 Formulation Development Brief summary, which is describing the development • 3.2.P.2.2.2 Overages Justification of Overages • 3.2.P.2.2.3 Physicochemical and Biological Properties Christa Clasen Ankara, 6./7. April 2006

  28. 3.2.P.2 Pharmaceutical Development • 3.2.P.2.3 Manufacturing Process Development Selection and optimisation of the manufacturing process with its particular critical steps • 3.2.P.2.4 Container Closure System Suitability of the Container Closure System used for storage, transportation and drug product Christa Clasen Ankara, 6./7. April 2006

  29. 3.2.P.2 Pharmaceutical Development • 3.2.P.2.5 Microbiological AttributesMicrobiological Attributes should be discussed • 3.2.P.2.6 Compatibility Compatibility of with reconstitution diluent(s) Christa Clasen Ankara, 6./7. April 2006

  30. 3.2.P.3 Manufacture • 3.2.P.3.1 Manufacturer(s) • 3.2.P.3.2 Batch Formula • 3.2.P.3.3 Description of Manufacturing Process and Process Controls • 3.2.P.3.4 Controls of Critical Steps • 3.2.P.3.5 Process Validation and/or Evaluation Christa Clasen Ankara, 6./7. April 2006

  31. 3.2.P.3 Manufacture • 3.2.P.3.1 Manufacturer(s) Name, address and responsibility of each manufacturer • 3.2.P.3.2 Batch Formula Batch formula incl. all components with amounts and references Christa Clasen Ankara, 6./7. April 2006

  32. 3.2.P.3 Manufacture • 3.2.P.3.3 Description of Manufacturing Process and Process Controls • Flow diagram • Narrative description of the manufacturing process • Process parameters • Proposals for justification of reprocessing of materials Christa Clasen Ankara, 6./7. April 2006

  33. 3.2.P.3 Manufacture • 3.2.P.3.4 Controls of Critical Steps and Intermediates • Critical Steps: Test and acceptance criteria • Intermediates: Information of quality and control • 3.2.P.3.5 Process validation and/or evaluation Description, documentation, results of validation and/or evaluation studies Christa Clasen Ankara, 6./7. April 2006

  34. 3.2.P.4 Control of Excipients • 3.2.P.4.1 Specifications • 3.2.P.4.2 Analytical Procedures • 3.2.P.4.3 Validation of Analytical Procedures • 3.2.P.4.4 Justification of Specification • 3.2.P.4.5 Excipients of Human or Animal Origin • 3.2.P.4.6 Novel Excipients Christa Clasen Ankara, 6./7. April 2006

  35. 3.2.P.4 Control of Excipients • 3.2.P.4.1 Specification Specification should be provided • 3.2.P.4.2 Analytical Procedure Analytical Procedures should be provided • 3.2.P.4.3 Validation of Analytical Procedures Information about Validation Christa Clasen Ankara, 6./7. April 2006

  36. 3.2.P.4 Control of Excipients • 3.2.P.4.4 Justification of Specification Justification for the proposed specification for the excipients • 3.2.P.4.5 Excipients of Human or Animal Origin Information regarding adventitious agens should be provided. • 3.2.P.4.6 Novel Excipients For excipients used the first time or by a new route of administration detailed information according to the Drug Substance format should be provided. Christa Clasen Ankara, 6./7. April 2006

  37. 3.2.P.5 Control of Drug Product • 3.2.P.5.1 Specification(s) • 3.2.P.5.2 Analytical Procedures • 3.2.P.5.3 Validation of Analytical Procedures • 3.2.P.5.4 Batch Analysis • 3.2.P.5.5 Characterisation of Impurities • 3.2.P.5.6 Justification of Specification(s) Christa Clasen Ankara, 6./7. April 2006

  38. 3.2.P.5 Control of Drug Product • 3.2.P.5.1 Specification(s) Specification(s) should be provided • 3.2.P.5.2 Analytical Procedures Analytical Procedures should be provided Christa Clasen Ankara, 6./7. April 2006

  39. 3.2.P.5 Control of Drug Product • 3.2.P.5.3 Validation of Analytical Procedures Analytical Validation should be provided • 3.2.P.5.4 Batch Analysis Descripition of batches and results of batch analysis should be provided Christa Clasen Ankara, 6./7. April 2006

  40. 3.2.P.5 Control of Drug Product • 3.2.P.5.5 Characterisation of Impurities Characterisation of Impurities  if not provided in 3.2.S.3.2 (Impurities) • 3.2.P.5.6 Justification of Specification(s) Justification of proposed specification(s) should be provided Christa Clasen Ankara, 6./7. April 2006

  41. 3.2.P.6 Reference Standards or Materials Information about reference standards or materials should be provided  if not provided in 3.2.S.5 „Reference standards or materials“ Christa Clasen Ankara, 6./7. April 2006

  42. 3.2.P.7 Container Closure System • Identity and specification of each primary packaging components • Brief description of non-functional secondary packaging component • Information about functional secondary packaging component Christa Clasen Ankara, 6./7. April 2006

  43. 3.2.P.8 Stability • 3.2.P.8.1 Stability Summary and Conclusion • 3.2.P.8.2 Post-approval Stability Protocol and Stability Commitment • 3.2.P.8.3 Stability Data Christa Clasen Ankara, 6./7. April 2006

  44. 3.2.P.8 Stability • 3.2.P.8.1 Stability Summary and Conclusion The Stability Summary should include: • Types of Studies • Results of Studies • Conclusion with respect to storage conditions and shelf-life Christa Clasen Ankara, 6./7. April 2006

  45. 3.2.P.8 Stability • 3.2.P.8.2 Post-approval Stability Protocol Post-approval stability protocoll and the stability commitment should be provided • 3.2.P.8.3 Stability Data • Presentation of the results in an appropriate format • Information of analytical procedures incl. validation Christa Clasen Ankara, 6./7. April 2006

  46. 3.2.A Appendices • 3.2.A.1 Facilities and Equipment • 3.2.A.2 Adventitious Agents Safety Evaluation • 3.2.A.3 Novel Excipients Christa Clasen Ankara, 6./7. April 2006

  47. 3.2.R Regional Information (EU) • Process Validation Scheme for Drug Product • Medical Devices • Certificate(s) of Suitability • TSE templates (place in 3.2.A.2) Christa Clasen Ankara, 6./7. April 2006

More Related